Mostrar el registro sencillo

dc.contributor.authorRoelsgaard, Ida K.
dc.contributor.authorIkdahl, Eirik
dc.contributor.authorRollefstad, Silvia
dc.contributor.authorWibetoe, Grunde
dc.contributor.authorEsbensen, Bente A.
dc.contributor.authorKitas, George D.
dc.contributor.authorRiel, Piet van
dc.contributor.authorGabriel, Sherine
dc.contributor.authorKvien, Tore K.
dc.contributor.authorDouglas, Karen
dc.contributor.authorWalberg-Jonsson, Solveig
dc.contributor.authorRantapaa Dahlqvist, Solbritt
dc.contributor.authorKarpouzas, George
dc.contributor.authorDessein, Patrick H.
dc.contributor.authorTsang, Linda
dc.contributor.authorEl-Gabalawy, Hani
dc.contributor.authorHitchon, Carol A.
dc.contributor.authorPascual-Ramos, Virginia
dc.contributor.authorContreras-Yañez, Irazu
dc.contributor.authorSfikakis, Petros P.
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.authorCrowson, Cynthia S.
dc.contributor.authorSemb, Anne Grete
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2020-08-25T13:00:02Z
dc.date.available2020-08-25T13:00:02Z
dc.date.issued2020
dc.identifier.issn1462-0324
dc.identifier.issn1462-0332
dc.identifier.urihttp://hdl.handle.net/10902/19079
dc.description.abstractObjectives: Smoking is a major risk factor for the development of both cardiovascular disease (CVD) and RA and may cause attenuated responses to anti-rheumatic treatments. Our aim was to compare disease activity, CVD risk factors and CVD event rates across smoking status in RA patients. Methods: Disease characteristics, CVD risk factors and relevant medications were recorded in RA patients without prior CVD from 10 countries (Norway, UK, Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico). Information on CVD events was collected. Adjusted analysis of variance, logistic regression and Cox models were applied to compare RA disease activity (DAS28), CVD risk factors and event rates across categories of smoking status. Results: Of the 3311 RA patients (1012 former, 887 current and 1412 never smokers), 235 experienced CVD events during a median follow-up of 3.5 years (interquartile range 2.5-6.1). At enrolment, current smokers were more likely to have moderate or high disease activity compared with former and never smokers (P < 0.001 for both). There was a gradient of worsening CVD risk factor profiles (lipoproteins and blood pressure) from never to former to current smokers. Furthermore, former and never smokers had significantly lower CVD event rates compared with current smokers [hazard ratio 0.70 (95% CI 0.51, 0.95), P = 0.02 and 0.48 (0.34, 0.69), P < 0.001, respectively]. The CVD event rates for former and never smokers were comparable. Conclusion: Smoking cessation in patients with RA was associated with lower disease activity and improved lipid profiles and was a predictor of reduced rates of CVD events.es_ES
dc.format.extent8 p.es_ES
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.rights© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatologyes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceRheumatology (Oxford) . 2020 Aug 1;59(8):1997-2004es_ES
dc.subject.otherRheumatoid Arthritises_ES
dc.subject.otherEpidemiologyes_ES
dc.subject.otherBehavioures_ES
dc.subject.otherQuality of Lifees_ES
dc.subject.otherOutcome Measureses_ES
dc.titleSmoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://www.doi.org/10.1093/rheumatology/kez557es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1093/rheumatology/kez557
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for RheumatologyExcepto si se señala otra cosa, la licencia del ítem se describe como © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology